Search Results
May 22, 2026, 03:09 ET Caliway Announces U.S. FDA IND Clearance for CBL-0302, Its Second Global Pivotal Phase 3 Study of CBL-514
participants in Taiwan and Australia, CBL-0206 utilizes a randomized, placebo-controlled, two-stage design. Stage 1 involves a 4:1 randomization (CBL-514 vs. placebo), while Stage 2 will provide CBL-514 treatment to all participants. Efficacy assessments align with the global strategy, utilizing MRI for fat
More news about: Caliway Biopharmaceuticals
May 22, 2026, 00:58 ET 2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable Safety
ongoing follow-up. The second stage of this study is currently ongoing, designed as a randomized head-to-head trial comparing this dose regimen vs. pembrolizumab plus chemotherapy in the first-line treatment of advanced NSCLC (all PD-L1 expression levels). 1) Mechanistic Rationale
More news about: Innovent Biologics
May 21, 2026, 22:01 ET Lang Van Sues Hanoi's BH Media in U.S. Federal Court Over Alleged Piracy of 5,252 Vietnamese Sound Recordings
its false copyright registration of the Vietnamese National Anthem (Tiến Quân Ca) caused the anthem to be muted during a live broadcast of a Vietnam vs. Laos football match, requiring intervention by Vietnam's Ministry of Foreign Affairs.The complaint also alleges that BH Media operated
More news about: Lang Van, Inc.
May 21, 2026, 20:00 ET 2026 ASCO | 科倫博泰2項 註冊研究入選2026 ASCO非小細胞肺癌口頭報告專場
評估的無進展生存期(PFS)，關鍵次要終點為總生存期(OS)。截至2025年9月29日，中位隨訪時間為10.5個月。研究結果顯示：PFS顯著改善：經BICR評估，蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗組較帕博利珠單抗組顯著延長PFS，中位PFS為尚未達到(NR) vs 5.7個月(風險比(HR)=0.35；95%置信區間(CI)：0.26-0.47；p<0.0001)。緩解率明顯提高：經BICR評估，蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗組客觀緩解率(ORR)為70.2%，帕博利珠單抗組為42.0%。OS尚未成熟但顯示積極獲益趨勢
More news about: 科倫博泰
May 21, 2026, 18:46 ET AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
AndroMETa-Lung-713: A phase 2/3 study of telisotuzumab adizutecan (ABBV-400, Temab-A) vs standard of care (SOC) in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
More news about: AbbVie
May 21, 2026, 17:30 ET Canopy Studies Selected for Oral and Poster Presentations at 2026 ASCO Annual Meeting
(Relative Risk 1.64; p<0.001) Longer time to treatment discontinuation: 79% longer median time to treatment discontinuation (224 vs. 125 days) Lower risk of hospitalization: 51% reduction in reported hospitalizations at 12 months (Relative Risk 0.49; p=0.011)
More news about: Canopy
May 21, 2026, 17:17 ET Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
pralsetinib met the primary progression-free survival (PFS) endpoint and had a significantly greater overall response rate and more durable response vs. standard of care, demonstrating the clinical utility of pralsetinib in RET fusion-positive NSCLC. In terms of safety, there were 32 (30.0%) and
More news about: Rigel Pharmaceuticals, Inc.
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
(98% vs 84%; 2.2% vs 0%), decreased white blood cells (82% vs 27%; 13% vs 0.6%), anemia (82% vs 28%; 1.6% vs 0%), decreased neutrophil count (80% vs 21%; 21.9% vs 2.6%), decreased lymphocyte count (53% vs 26%; 7.6% vs 1.9%), decreased platelet count (36% vs 12%; 1.9% vs 0.6%), increased ALT (48% vs 25%;
More news about: Eli Lilly and Company
May 21, 2026, 17:00 ET Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026
3+ tumor cell proportions ≥10%, as identified by AI analysis, achieve substantially higher response rates compared to those below the threshold (80% vs. 36.4%). The study demonstrates how integrated AI-powered HER2 and spatial tumor microenvironment analysis may help identify patients more likely to benefit
More news about: Lunit
May 21, 2026, 17:00 ET Sapience Therapeutics Provides Positive Data Update from Phase 2 Trial of Lucicebtide Plus SOC in Patients with Glioblastoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
10.1056/NEJMoa043330.PMID: 157580095 Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017;318(23):2306–2316. doi:10.1001/jama.2017.187186
More news about: Sapience Therapeutics, Inc.
May 21, 2026, 17:00 ET Boehringer Ingelheim's oncology portfolio shows strong promise across multiple cancers at ASCO 2026
being evaluated as a first-line treatment vs. atezolizumab plus SOC chemotherapy in a Phase III trial for patients with ES-SCLC (DAREON®-LUNG-1).15 Additionally, a Phase III trial is ongoing to evaluate obrixtamig in combination with SOC chemotherapy vs. chemotherapy alone as first-line treatment
More news about: Boehringer Ingelheim
May 21, 2026, 17:00 ET New Clinical Data for Izalontamab Brengitecan and Novel ADC Pipeline to be Presented at ASCO 2026
triple-negative breast cancer patients in ChinaSafety and efficacy data from a randomized, open label, multi-center, Phase III study evaluating iza-bren vs physician's choice of chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma in ChinaDemonstrating
More news about: SystImmune, Inc.
May 21, 2026, 16:54 ET Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
efficacy endpoint, defined as the proportion of patients achieving a serum uric acid (sUA) level <6 mg/dL at month 6 (75 mg: 69.2% vs 8.1%; p<0.0001; 50 mg: 56.6% vs 8.1%; p<0.0001). The safety profile was consistent with previous studies. Detailed results are expected to be presented at a
More news about: Swedish Orphan Biotrauma AB
May 21, 2026, 16:51 ET Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
efficacy endpoint, defined as the proportion of patients achieving a serum uric acid (sUA) level <6 mg/dL at month 6 (75 mg: 69.2% vs 8.1%; p<0.0001; 50 mg: 56.6% vs 8.1%; p<0.0001). The safety profile was consistent with previous studies. Detailed results are expected to be presented at a
More news about: Swedish Orphan Biotrauma AB
May 21, 2026, 16:05 ET CAE reports fourth quarter and full fiscal year 2026 results and targets significant cost savings and profitability growth as part of transformation plan
FFSs and long-term training and digital flight services contracts.For the year, Civil booked orders for $2.6 billion, including 42 FFS sales (vs. 56 in the prior fiscal year) and comprehensive, long-term training agreements with customers worldwide.The Civil book-to-sales ratio was 1.29x
More news about: CAE Inc.
May 21, 2026, 15:38 ET LG destaca estratégia integrada para data centers e reforça atuação em soluções para a era da IA
reorganizou suas operações em quatro divisões de negócios: Home Appliance Solution (HS), Media Entertainment Solution (MS), Vehicle Solution (VS) e Eco Solution (ES), redefinindo seus papéis e identidades para acelerar sua visão de futuro até 2030. Em 2024, as quatro divisões combinadas
More news about: LG Electronics Brasil
May 21, 2026, 15:33 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
channel stuffing scheme and an undisclosed related party distributor" and "estimat[ing] that, absent channel stuffing, ADMA revenues declined 3% in 2025 vs. +20% reported."Following publication of the Culper report, ADMA's stock price fell $2.26 per share, or 16.63%, to close at $11.33 per share on
More news about: Pomerantz LLP
May 21, 2026, 14:30 ET Carnival Corporation Marks First Meal Donation in Latin America
spans dozens of small and large programs, practices and technologies across its world-class cruise lines, designed to cut food waste by 50% by 2030 (vs. 2019).About Carnival Corporation Carnival Corporation is the largest global cruise company and among the largest leisure travel
More news about: Carnival Corporation Ltd.
May 21, 2026, 13:35 ET CRAFTSMAN® Launches New V20* ADVANCED™ Batteries to Help DIYers Power Through More Demanding Jobs
(w/out a workload) is 20 volts. Nominal voltage is 18. † vs. CMCB202 2Ah battery, more runtime based on 10 Amp discharge test, not in application.** Less temperature rise during full discharge, not in application vs. CMCB202 2 Ah battery.ⱡ Limit of (1) free CRAFTSMAN V20* 3Ah
More news about: CRAFTSMAN
May 21, 2026, 11:06 ET LG amplia disponibilidade global do novo Chiller Scroll Inverter com condensação a ar e refrigerante R32
reorganizou suas operações em quatro divisões de negócios: Home Appliance Solution (HS), Media Entertainment Solution (MS), Vehicle Solution (VS) e Eco Solution (ES), redefinindo seus papéis e identidades para acelerar sua visão de futuro até 2030. Em 2024, as quatro divisões combinadas
More news about: LG Electronics Brasil
May 21, 2026, 11:00 ET Electric Era Launches CoPower Platform to Unlock Data Center Revenue Growth Constrained by Grid Power Limits
building blocks deployable individually or combined to deliver 100+ MW of added capacityRapid deployment: 12-18 month installation timeline vs. 5-7+ years for traditional utility upgradesPower availability: 99.99% power availability achieved via autonomous operational software,
More news about: Electric Era
May 21, 2026, 10:30 ET Fertility Pregnancy Rapid Test Kits Market to Reach USD 2.6 Billion by 2036 as Connected Reproductive Health Platforms and Consumer Self-Testing Trends Transform the Industry
Production and sourcing insights: Diagnostic materials, hormone assay components, and manufacturing economicsPricing benchmarks: Cost-to-produce vs. retail pricing across product formats and regionsTrade flow analysis: Import-export dynamics for diagnostic devices and reproductive health
More news about: Future Market Insights
May 21, 2026, 10:00 ET Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL
content:https://www.prnewswire.com/news-releases/guangzhou-lupengnewave-pharmaceutical-inc-enrolled-the-first-patient-in-the-global-phase-3-rocket-cll-trial-evaluating-rocbrutinib-lp-168-vs-pirtobrutinib-in-rr-cllsll-302779014.htmlSOURCE
More news about: Lupeng Pharmaceutical Ltd
May 21, 2026, 09:00 ET PHR Shareholder Alert: Phreesia, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
represented a reduction of up to $39 million from the original projection, suggesting the gap did not materialize overnightInside Knowledge vs. Public StatementsThe action alleges a pattern: public reassurance followed by private awareness of contrary data. In May 2025,
More news about: SueWallSt.com
May 21, 2026, 09:00 ET GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Placebo Response Risks: SueWallSt
walk improvements, a phenomenon management later called "quite fascinating" but never warned investors about beforehandInside Knowledge vs. Public StatementsThe securities action alleges that while management had real-time visibility into the trial's geographic enrollment
More news about: SueWallSt.com